Amanote Research
Register
Sign In
Safety, Cost and Effectiveness Issues With Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
Annals of the Rheumatic Diseases
- United Kingdom
doi 10.1136/ard.58.2008.i86
Full Text
Open PDF
Abstract
Available in
full text
Categories
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Date
November 1, 1999
Authors
J. F Fries
Publisher
BMJ
Related search
Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients With Rheumatoid Arthritis?
Neurotherapeutics
Neurology
Pharmacology
OP0281-HPR Preferences of Patients With Rheumatoid Arthritis Regarding Disease Modifying Anti-Rheumatic Drugs: A Discrete Choice Experiment
Effect of Disease-Modifying Anti-Rheumatic Drugs on Bone Structure and Strength in Psoriatic Arthritis Patients
Arthritis Research & Therapy
Biological Targets in the Treatment of Rheumatoid Arthritis: A Comprehensive Review of Current and In-Development Biological Disease Modifying Anti-Rheumatic Drugs
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Efficacy and Safety of Sirukumab in Japanese Patients With Moderate to Severe Rheumatoid Arthritis Inadequately Controlled by Disease Modifying Anti-Rheumatic Drugs: Subgroup Analysis of a Phase 3 Study
Modern Rheumatology
Medicine
Rheumatology
Lipid Profiles in Rheumatoid Arthritis Patients Treated With Disease-Modifying Antirheumatic Drugs
Reumatologia
Rheumatology
Allergy
Immunology
Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Factors Associated With Quality of Life and Functional Disability Among Rheumatoid Arthritis Patients Treated With Disease-Modifying Anti-Rheumatic Drugs for at Least Six-Months
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
THU0094 Factors Associated With Radiographic Remission (RR) in Patients With Rheumatoid Arthritis (RA) While Non-Biologicaldisease Modifying Anti-Rheumatic Drugs (DMARDS) Using
